The Federal Trade Commission’s (FTCs) Bureau of Consumer Protection today announced the issuance of Health Products Compliance Guidance, the agency’s first revision of its business guidance in this area in nearly 25 years. One major revision is to extend the guidance covering dietary supplements to all health-related products.
The revised guide also reflects updates to other FTC guidance documents, including the guidance on endorsements and testimonials. Among other things, the new guide includes a much more detailed discussion of the amount and type of evidence needed to substantiate health-related claims, with more emphasis on the fact that the FTC, as a general rule, expects high quality randomized, controlled human clinical trials.
Related Posts
American Telemedicine Association Publishes New Health Data Privacy Principles
Amid rising concerns about data privacy within the telehealth arena, the American Telemedicine Association (ATA) released a set of principles to ensure patient data is protected during telehealth utilization. The ATA’s Health Data Privacy Principles include six components: The ATA states that a federal policy would offer much-needed consistency in data privacy practices for telehealth providers…
New Federal Resource on Protecting the Privacy and Security of Consumer’s Health Information
The Federal Trade Commission (FTC) and the Department of Health and Human Services (HHS) recently released a joint publication that provides guidance and practical advice to all entities that collect, share, or use consumer information. Collecting, Using, or Sharing Consumer Health Information gathers all of the various legal obligations in one place and focuses on…
Congressional White Paper Recommends a Sector-by-Sector Approach to Regulating Artificial Intelligence
Senate Health Committee ranking Republican Bill Cassidy (LA) released a white paper on September 6 suggesting Congress refrain from crafting a government-wide approach to overseeing artificial intelligence and only step in when an agency’s oversight falls short, such as filling gaps in U.S. Food and Drug Administration’s (FDA) ability to regulate artificial intelligence (AI) as…